Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 46


Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients.

Fourdinier O, Schepers E, Metzinger-Le Meuth V, Glorieux G, Liabeuf S, Verbeke F, Vanholder R, Brigant B, Pletinck A, Diouf M, Burtey S, Choukroun G, Massy ZA, Metzinger L; European Uremic Toxin Work Group-EUTox.

Sci Rep. 2019 Mar 14;9(1):4477. doi: 10.1038/s41598-019-41101-8.


Gut microbiota dynamics and uraemic toxins: one size does not fit all.

Joossens M, Faust K, Gryp T, Nguyen ATL, Wang J, Eloot S, Schepers E, Dhondt A, Pletinck A, Vieira-Silva S, Falony G, Vaneechoutte M, Vanholder R, Van Biesen W, Huys GRB, Raes J, Glorieux G.

Gut. 2018 Nov 21. pii: gutjnl-2018-317561. doi: 10.1136/gutjnl-2018-317561. [Epub ahead of print] No abstract available.


Cardiovascular disease after transplantation: an emerging role of the immune system.

Van Laecke S, Malfait T, Schepers E, Van Biesen W.

Transpl Int. 2018 Jul;31(7):689-699. doi: 10.1111/tri.13160. Epub 2018 Apr 30. Review.


Increased urinary osmolyte excretion indicates chronic kidney disease severity and progression rate.

Gil RB, Ortiz A, Sanchez-Niño MD, Markoska K, Schepers E, Vanholder R, Glorieux G, Schmitt-Kopplin P, Heinzmann SS.

Nephrol Dial Transplant. 2018 Dec 1;33(12):2156-2164. doi: 10.1093/ndt/gfy020.


Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update.

Vanholder R, Pletinck A, Schepers E, Glorieux G.

Toxins (Basel). 2018 Jan 8;10(1). pii: E33. doi: 10.3390/toxins10010033. Review.


Assessment of the association between increasing membrane pore size and endotoxin permeability using a novel experimental dialysis simulation set-up.

Schepers E, Glorieux G, Eloot S, Hulko M, Boschetti-de-Fierro A, Beck W, Krause B, Van Biesen W.

BMC Nephrol. 2018 Jan 5;19(1):1. doi: 10.1186/s12882-017-0808-y.


Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker.

Pontillo C, Zhang ZY, Schanstra JP, Jacobs L, Zürbig P, Thijs L, Ramírez-Torres A, Heerspink HJL, Lindhardt M, Klein R, Orchard T, Porta M, Bilous RW, Charturvedi N, Rossing P, Vlahou A, Schepers E, Glorieux G, Mullen W, Delles C, Verhamme P, Vanholder R, Staessen JA, Mischak H, Jankowski J.

Kidney Int Rep. 2017 Nov;2(6):1066-1075. doi: 10.1016/j.ekir.2017.06.004.


Spontaneous variability of pre-dialysis concentrations of uremic toxins over time in stable hemodialysis patients.

Eloot S, Van Biesen W, Roels S, Delrue W, Schepers E, Dhondt A, Vanholder R, Glorieux G.

PLoS One. 2017 Oct 10;12(10):e0186010. doi: 10.1371/journal.pone.0186010. eCollection 2017.


Binding of bromocresol green and bromocresol purple to albumin in hemodialysis patients.

Delanghe S, Biesen WV, Velde NV, Eloot S, Pletinck A, Schepers E, Glorieux G, Delanghe JR, Speeckaert MM.

Clin Chem Lab Med. 2018 Feb 23;56(3):436-440. doi: 10.1515/cclm-2017-0444.


The Place of Large Pore Membranes in the Treatment Portfolio of Patients on Hemodialysis.

Van Biesen W, Vanholder R, Schepers E, Glorieux G, Dhondt A, Eloot S.

Contrib Nephrol. 2017;191:168-177. doi: 10.1159/000479265. Epub 2017 Sep 14. Review.


Quantification of carbamylated albumin in serum based on capillary electrophoresis.

Delanghe S, Moerman A, Pletinck A, Schepers E, Glorieux G, Van Biesen W, Delanghe JR, Speeckaert MM.

Electrophoresis. 2017 Sep;38(17):2135-2140. doi: 10.1002/elps.201700068. Epub 2017 Jun 30.


Hereditary polycystic kidney disease is characterized by lymphopenia across all stages of kidney dysfunction: an observational study.

Van Laecke S, Kerre T, Nagler EV, Maes B, Caluwe R, Schepers E, Glorieux G, Van Biesen W, Verbeke F.

Nephrol Dial Transplant. 2018 Mar 1;33(3):489-496. doi: 10.1093/ndt/gfx040.


Metabolic profiling of human plasma and urine in chronic kidney disease by hydrophilic interaction liquid chromatography coupled with time-of-flight mass spectrometry: a pilot study.

Boelaert J, Lynen F, Glorieux G, Schepers E, Neirynck N, Vanholder R.

Anal Bioanal Chem. 2017 Mar;409(8):2201-2211. doi: 10.1007/s00216-016-0165-x. Epub 2017 Jan 12.


Determination of Asymmetric and Symmetric Dimethylarginine in Serum from Patients with Chronic Kidney Disease: UPLC-MS/MS versus ELISA.

Boelaert J, Schepers E, Glorieux G, Eloot S, Vanholder R, Lynen F.

Toxins (Basel). 2016 May 13;8(5). pii: E149. doi: 10.3390/toxins8050149.


New insights in molecular mechanisms involved in chronic kidney disease using high-resolution plasma proteome analysis.

Glorieux G, Mullen W, Duranton F, Filip S, Gayrard N, Husi H, Schepers E, Neirynck N, Schanstra JP, Jankowski J, Mischak H, Argilés À, Vanholder R, Vlahou A, Klein J.

Nephrol Dial Transplant. 2015 Nov;30(11):1842-52. doi: 10.1093/ndt/gfv254. Epub 2015 Jul 9.


Transcriptome analysis in patients with chronic kidney disease on hemodialysis disclosing a key role for CD16+CX3CR1+ monocytes.

Schepers E, Houthuys E, Dhondt A, De Meyer G, Neirynck N, Bernaert P, Van den Bergh R, Brouckaert P, Vanholder R, Glorieux G.

PLoS One. 2015 Apr 1;10(4):e0121750. doi: 10.1371/journal.pone.0121750. eCollection 2015.


Soluble tumor necrosis factor receptor 1 and 2 predict outcomes in advanced chronic kidney disease: a prospective cohort study.

Neirynck N, Glorieux G, Schepers E, Verbeke F, Vanholder R.

PLoS One. 2015 Mar 30;10(3):e0122073. doi: 10.1371/journal.pone.0122073. eCollection 2015.


Chronic kidney disease progression is mainly associated with non-recovery of acute kidney injury.

D'hoore E, Neirynck N, Schepers E, Vanholder R, Verbeke F, Van Thielen M, Van Biesen W.

J Nephrol. 2015 Dec;28(6):709-16. doi: 10.1007/s40620-015-0181-5. Epub 2015 Feb 21.


Pro-inflammatory cytokines and leukocyte oxidative burst in chronic kidney disease: culprits or innocent bystanders?

Neirynck N, Glorieux G, Schepers E, Dhondt A, Verbeke F, Vanholder R.

Nephrol Dial Transplant. 2015 Jun;30(6):943-51. doi: 10.1093/ndt/gfu409. Epub 2015 Jan 20.


Supplemental Content

Loading ...
Support Center